Secondary Logo

Journal Logo


Recent Developments Pertaining to H. pylori Infection

Howden, Colin W. MD, FACG1; Graham, David Y. MD, MACG2

Author Information
The American Journal of Gastroenterology: January 2021 - Volume 116 - Issue 1 - p 1-3
doi: 10.14309/ajg.0000000000001031
  • Free

A 2017 guideline from the American College of Gastroenterology (ACG) expanded potential indications for testing for Helicobacter pylori infection, altered recommendations for first- and second-line treatment, and called for routine post-treatment testing (1). Some more recent publications suggest that current practice can be improved.


H. pylori is the major etiologic factor for gastric adenocarcinoma and may cause more cancers worldwide than hepatitis B and C viruses combined (2). The American Cancer Society has predicted more new cases and attributable deaths annually from gastric cancer than from both types of esophageal cancer (3). Pangastritis with metaplastic epithelia (pseudopyloric and intestinal metaplasia) signifies an increased risk of gastric cancer; all patients with metaplastic epithelium should be tested for H. pylori infection and treated for it if positive (4,5).

The Kyoto and Houston consensus conferences also recommended treating all individuals with proven H. pylori infection (6,7). An updated Cochrane Collaboration systematic review and meta-analysis of randomized controlled trials (RCTs) reported that H. pylori eradication in otherwise healthy adults was associated with a 46% reduced incidence of, and a 39% reduced mortality from, gastric cancer (8). However, because all included RCTs were from Asia or South America, the results may not be automatically generalizable to the United States. From South Korea, another RCT showed that treating the infection in first-degree relatives of gastric cancer patients significantly reduced their risk of gastric cancer (9). This was despite the known higher rate of reinfection in Asia than elsewhere.

Recent evidence from the United States using the Veterans Health Administration database showed that eradication of H. pylori infection was associated with a 76% reduced incidence of gastric cancer among those participants who were diagnosed accurately, treated, and had a post-treatment test that confirmed eradication (10). Finally, a large cohort study from Taiwan has demonstrated the effectiveness of a mass screening and treatment program among a population with a high prevalence of H. pylori infection and gastric cancer (11). With intensive screening and treatment, the incidence of—and mortality from—gastric cancer fell by 53% and 25%, respectively.


An important precept in the 2017 ACG guideline was that all patients be retested post-treatment (1). However, in the recent Veterans Health Administration study (10), only approximately 20% of treated patients had documented post-treatment testing (10,12) and other studies confirm that post-treatment testing is performed infrequently and inconsistently (13,14).

Traditionally, antimicrobial therapy is predicated on results of susceptibility testing. With H. pylori, susceptibility testing is available from a few large commercial laboratories. Molecular testing using gastric biopsies or fecal samples is in development but is available commercially (e.g.,

There are scarce data available concerning contemporary antimicrobial resistance rates in North America; Table 1 lists estimates from the ACG 2017 guideline (1) and more recent results from subsequent studies (15–17). A systematic review and meta-analysis of international studies (18) included only 2 from North America that were referenced in the 2017 ACG guideline (1).

Table 1.
Table 1.:
Reported antimicrobial resistance rates by H. pylori


Given the high rates of resistance to clarithromycin, metronidazole, and levofloxacin, these should no longer be used in triple regimens unless based on susceptibility testing. Treatment decisions regarding the use of empiric therapy should be based on knowledge of the patient's antibiotic history and the presence or absence of true penicillin allergy (1). Empiric therapy should reliably achieve high local cure rates despite the absence of susceptibility testing. Two regimens approved by the US Food and Drug Administration (FDA) that can be used empirically are bismuth quadruple therapy (BQT) and rifabutin triple therapy.

BQT should contain tetracycline rather than doxycycline and be given for 14 days (19). BQT empiric therapy proved as successful as susceptibility-guided therapy in a RCT from China (20). However, problems persist with BQT including its complexity, large pill burden, adverse effects, and availability and cost of tetracycline, which may be obtained less expensively using GoodRx or similar services. A combination product (Pylera, Allergan, Madison, NJ) is available but is expensive and packaged as a 10-day course (21), which may cause issues when prescribed for the desired 14 days.

The 2017 ACG guideline also recommended concomitant/non-bismuth quadruple therapy as first-line (1). However, it has fallen into disfavor because it requires giving clarithromycin and metronidazole together such that failure requires dual clarithromycin-metronidazole resistance. However, when successful, all patients will receive one unnecessary antibiotic, which can only contribute to global antimicrobial resistance.

In 2019, the FDA approved a 3-in-1 combination product of omeprazole, amoxicillin, and rifabutin for the treatment of H. pylori infection in adults (Talicia, RedHill Biopharma, Raleigh, NC). Eradication rates were not influenced by clarithromycin or metronidazole resistance, and no resistance was documented to rifabutin either pretreatment or post-treatment (Table 1). In a RCT, non-Asian, treatment-naïve patients given the triple combination had an intent-to-treat (ITT) eradication rate of 83.8% compared with 57.7% in those given equivalent doses of omeprazole and amoxicillin without rifabutin (16). It was well tolerated with high adherence. This product only became available after the 2017 ACG guideline (1). It is appropriate for either first-line or salvage treatment based on its FDA approval.

Potassium-competitive acid blockers are acid-suppressing agents that interact with the gastric proton pump differently to conventional proton pump inhibitors. They produce earlier onset of acid suppression and more consistent 24-hour control of intragastric acidity than proton pump inhibitors (22,23). The potassium-competitive acid blocker vonoprazan is licensed in some Asian and South American countries but not currently available in the United States. A RCT from Japan compared 7 days of treatment with relatively low doses of vonoprazan and amoxicillin with vonoprazan, amoxicillin, and clarithromycin. ITT eradication rates were 84.5% and 89.2%, respectively. Among patients with clarithromycin-resistant strains, eradication rates were 92.3% and 76.2% for the dual and triple regimens, respectively (24). Optimization of dosing and treatment duration will likely produce even higher eradication rates. Vonoprazan dual and triple regimens are currently being evaluated in a phase 3 trial in the United States and Europe (Phathom Pharmaceuticals, Buffalo Grove, IL) in which patients are being treated for 14 days and with higher doses.


Recent guidelines recommend treating all individuals infected with H. pylori. Despite practice recommendations (1), post-treatment testing is still not being performed routinely (10,12–14). This prevents patients from knowing whether they have been cured—and physicians from learning whether their treatment was effective. Triple regimens containing clarithromycin, metronidazole, or levofloxacin should no longer be used without pretreatment susceptibility testing. Concomitant therapy exposes patients to unnecessary antibiotics. Approved therapies that can be used empirically are BQT and rifabutin triple therapy.


Guarantor of the article: Colin W. Howden MD, FACG.

Specific author contributions: Each author contributed equally to the writing of the manuscript and review of source documents. Each approved the submitted version.

Financial support: Dr. Graham is supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service grant DK56338 which funds the Texas Medical Center Digestive Diseases Center. There was no financial support for the preparation of this article.

Potential competing interests: Dr. Howden is a consultant for Alfasigma US, Clexio, Ironwood, Phathom Pharmaceuticals, and RedHill Biopharma and a member of the speakers' bureau for Alfasigma US, Alnylam, and RedHill Biopharma. Dr. Graham is a consultant for RedHill Biopharma and Phathom Pharmaceuticals regarding novel H. pylori therapies. He has received research support for the culture of Helicobacter pylori and is the PI of an international study of the use of antimycobacterial therapy for Crohn's disease.


1. Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol 2017;112:212–39.
2. de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. Lancet Glob Health 2020;8:e180–90.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7–30.
4. Graham DY, Rugge M, Genta RM. Diagnosis: Gastric intestinal metaplasia – what to do next? Curr Opin Gastroenterol 2019;35:535–43.
5. Gupta S, Li D, El Serag HB, et al. AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology 2020;158:693–702.
6. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015;64:1353–67.
7. El-Serag HB, Kao JY, Gilger M, et al. Houston Consensus Conference on testing for Helicobacter pylori in the United States. Clin Gastroenterol Hepatol 2018;16:992–1002.
8. Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: Systematic review and meta-analysis. Gut 2020. [Epub ahead of print March 23, 2020.]
9. Choi IJ, Kim CG, Lee JY, et al. Family history of gastric cancer and Helicobacter pylori treatment. New Engl J Med 2020;382:427–36.
10. Kumar S, Metz DC, Ellenberg S, et al. Risk factors and incidence of gastric cancer after detection of Heicobacter pylori infection: A large cohort study. Gastroenterology 2020;158:527–36.
11. Chiang TH, Chang WJ, Chen SLS, et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: A long-term cohort study on Matsu Islands. Gut 2020. [Epub ahead of print August 13, 2020.].
12. Howden CW. One step forward but room for improvement in reducing risk of gastric cancer by curing Helicobacter pylori infection. Gastroenterology 2020;158:466–7.
13. Kumar S, Metz DC, Kaplan DE, et al. Low rates of retesting for eradication of Helicobacter pylori infection after treatment in the Veterans Health Administration. Clin Gastroenterol Hepatol 2020. [Epub ahead of print April 6, 2020.]
14. Vakil N, Michalopoulos SN, Zajichek A, et al. Helicobacter pylori testing and treatment in a large, integrated healthcare delivery system in the United States. Gastroenterology 2019;156:Su1266. (Abstract).
15. Kumar S, Sangitha R, Nachamkin I, et al. Resistance patterns of refractory Helicobacter pylori infection in a referral centre in the Delaware Valley. GastroHep 2020;2:6–12.
16. Graham DY, Cannan Y, Maher J, et al. Rifabutin-based triple therapy (RHB-105) for Helicobacter pylori eradication: A double-blind, randomized, controlled trial. Ann Intern Med 2020;172:795–802.
17. Nyssen OP, Bordin D, Tepes B, et al. European registry on Helicobacter pylori management (Hp-EuReg): Patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21,533 patients. Gut 2020. [Epub ahead of print September 21, 2020.]
18. Kasahun GG, Demoz GT, Desta DM. Primary resistance pattern of Helicobacter pylori to antibiotics in adult population: A systematic review. Infect Drug Resist 2020;13:1567–73.
19. Alsamman MA, Vecchio EC, Shawwa K, et al. Retrospective analysis confirms tetracycline quadruple as best Helicobacter pylori regimen in the USA. Dig Dis Sci 2019;64:2893–8.
20. Chen Q, Long X, Ji Y, et al. Randomised controlled trial: Susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Aliment Pharmacol Ther 2019;49:1385–94.
21. Allergan USA. Pylera: Highlights of prescribing information. ( Accessed July 17, 2020.
22. Takeuchi T, Furuta T, Fujiwara Y, et al. Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH Study). Aliment Pharmacol Ther 2020;51:534 – 43.
23. Han S, Choi HY, Kim YH, et al. Randomised clinical trial: Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 2019;50:751–9.
24. Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: A multicentre randomised trial in Japan. Gut 2020;69:1019–26.
© 2020 by The American College of Gastroenterology